Bayer, Orion prostate cancer drug cuts risk of metastasis or death by more than 50% in key study
As Merck and Bristol-Myers look toward prostate cancer as the next battleground for immuno-oncology dominance, Bayer and partner Orion broke out the numbers that showed their drug, darolutamide, cut the risk of metastasis or death by 59% in a late-stage trial in patients with non-metastatic castration-resistant prostate cancer (nmCRPC).
The companies first reported the drug had met the main goal in the ARAMIS trial last October. The trial tested darolutamide against a placebo in more than 1,500 patients with non-metastatic castration-resistant prostate cancer (nmCRPC) that were already on standard-of-care androgen deprivation therapy, and were at high risk of the disease spreading.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.